肥胖型多囊卵巢综合征的中西医治疗研究进展
Research Progress on the Treatment of Obesity-Related Polycystic Ovary Syndrome with Traditional Chinese and Western Medicine
DOI: 10.12677/jcpm.2026.52111, PDF,   
作者: 孟黎明, 刘毛毛:济宁医学院临床医学院,山东 济宁;姚红梅*:济宁医学院附属医院妇科,山东 济宁
关键词: 多囊卵巢综合征肥胖西医治疗中医治疗治疗进展Polycystic Ovary Syndrome Obesity Western Medical Treatment Traditional Chinese Medical Treatment Treatment Progress
摘要: 多囊卵巢综合征(Polycystic Ovary Syndrome, PCOS)是一种常见的妇科内分泌疾病,在育龄期女性中发病率约为6%~13%。PCOS的临床表现复杂多样,如月经紊乱、不孕等生殖系统症状,以及肥胖、胰岛素抵抗等代谢异常表现。肥胖不仅加重PCOS的症状,远期还可增加糖尿病以及心血管疾病的发病风险。近年来,随着对PCOS与肥胖之间关系的深入研究,对PCOS肥胖的治疗方法也在不断优化,本文通过对相关研究的阅读及分析,探讨肥胖型PCOS的中西医治疗最新研究进展,旨在为临床实践提供更新的参考,以期改善肥胖型PCOS患者的生育及代谢健康状况。
Abstract: Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrine disorders affecting women of reproductive age, with epidemiological studies indicating a global prevalence ranging from 6% to 13%, depending on diagnostic criteria and population characteristics. It is characterized by a triad of clinical features: chronic anovulation, hyperandrogenism, and polycystic ovarian morphology observed via ultrasound. Beyond these core manifestations, PCOS is frequently accompanied by a range of metabolic disturbances, among which obesity stands out as both a common comorbidity and a significant exacerbating factor. Approximately 40% to 80% of women diagnosed with PCOS are overweight or obese, particularly exhibiting central adiposity, which further intensifies insulin resistance, dyslipidemia, and systemic inflammation—key contributors to long-term complications such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. The interplay between obesity and PCOS creates a vicious cycle: excess body weight worsens hormonal imbalances and ovulatory dysfunction, while the underlying pathophysiology of PCOS, including hyperinsulinemia and altered adipokine secretion, promotes fat accumulation and makes weight loss more challenging. Given this bidirectional relationship, effective management of obesity has become a cornerstone in the treatment strategy for PCOS, aiming not only to improve fertility outcomes but also to mitigate metabolic risks. This article, through reading and analyzing relevant research, explores the latest research progress in the treatment of obese PCOS with both traditional Chinese and Western medicine, aiming to provide updated references for clinical practice and improve the reproductive and metabolic health of obese PCOS patients.
文章引用:孟黎明, 刘毛毛, 姚红梅. 肥胖型多囊卵巢综合征的中西医治疗研究进展[J]. 临床个性化医学, 2026, 5(2): 136-144. https://doi.org/10.12677/jcpm.2026.52111

参考文献

[1] Benham, J.L., Goldberg, A., Teede, H. and Tay, C.T. (2023) Polycystic Ovary Syndrome: Associations with Cardiovascular Disease. Climacteric, 27, 47-52. [Google Scholar] [CrossRef] [PubMed]
[2] Zafar, N., Qureshi, R., Siddiqa, A., Mustafa Naqvi, S.A., Waheed, F., Mashwani, Z., et al. (2025) From Root to Recovery: The Role of Herbs in Polycystic Ovary Syndrome Management. Steroids, 218, Article ID: 109606. [Google Scholar] [CrossRef] [PubMed]
[3] 欧阳雅囡, 隋娟, 李艳. 肥胖型多囊卵巢综合征发病机制及减重治疗的研究进展[J]. 生殖医学杂志, 2025, 34(9): 1290-1295.
[4] Barber, T.M. (2022) Why Are Women with Polycystic Ovary Syndrome Obese? British Medical Bulletin, 143, 4-15. [Google Scholar] [CrossRef] [PubMed]
[5] Li, W., Liu, C., Yang, Q., Zhou, Y., Liu, M. and Shan, H. (2022) Oxidative Stress and Antioxidant Imbalance in Ovulation Disorder in Patients with Polycystic Ovary Syndrome. Frontiers in Nutrition, 9, Article ID: 1018674. [Google Scholar] [CrossRef] [PubMed]
[6] Barber, T.M., McCarthy, M.I., Wass, J.A.H. and Franks, S. (2006) Obesity and Polycystic Ovary Syndrome. Clinical Endocrinology, 65, 137-145. [Google Scholar] [CrossRef] [PubMed]
[7] Rambaran, N. and Islam, M.S. (2025) Decoding Androgen Excess in Polycystic Ovary Syndrome: Roles of Insulin Resistance and Other Key Intraovarian and Systemic Factors. World Journal of Diabetes, 16, Article ID: 108789. [Google Scholar] [CrossRef] [PubMed]
[8] Xing, C., Zhao, H., Zhang, J. and He, B. (2022) Effect of Metformin versus Metformin Plus Liraglutide on Gonadal and Metabolic Profiles in Overweight Patients with Polycystic Ovary Syndrome. Frontiers in Endocrinology, 13, Article ID: 945609. [Google Scholar] [CrossRef] [PubMed]
[9] Rahim, S. and Pergolizzi, J. (2025) The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Agonists for Polycystic Ovary Syndrome. Cureus, 17, e77998. [Google Scholar] [CrossRef] [PubMed]
[10] Senthilkumar, H. and Arumugam, M. (2025) Gut Microbiota: A Hidden Player in Polycystic Ovary Syndrome. Journal of Translational Medicine, 23, Article No. 443. [Google Scholar] [CrossRef] [PubMed]
[11] Hong, Y., Lee, J., Vu, T.H., Lee, S., Lillehoj, H.S. and Hong, Y.H. (2021) Exosomes of Lipopolysaccharide-Stimulated Chicken Macrophages Modulate Immune Response through the MyD88/NF-κB Signaling Pathway. Developmental & Comparative Immunology, 115, Article ID: 103908. [Google Scholar] [CrossRef] [PubMed]
[12] 王子璐, 刘文琼. 肥胖型多囊卵巢综合征中医辨治思路[J]. 云南中医中药杂志, 2025, 46(10): 16-21.
[13] 马玉佩, 杨立宏. 多囊卵巢综合征病因病机及中西医治疗最新进展[J]. 临床合理用药, 2025, 18(30): 178-181.
[14] 李文, 杨立宏. 痰湿证多囊卵巢综合征的中西医治疗进展[J]. 中国现代医生, 2025, 63(31): 128-131.
[15] Turetta, C., Giannini, A., Tarsitano, M.G., Gianfrilli, D., Paoli, A., Kontopantelis, E., et al. (2025) Impact of Ketogenic Diet on Weight, Metabolic, and Endocrine Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Gynecologic and Obstetric Investigation, 90, 515-534. [Google Scholar] [CrossRef] [PubMed]
[16] Kazemi, M., Kim, J.Y., Wan, C., Xiong, J.D., Michalak, J., Xavier, I.B., et al. (2022) Comparison of Dietary and Physical Activity Behaviors in Women with and without Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of 39 471 Women. Human Reproduction Update, 28, 910-955. [Google Scholar] [CrossRef] [PubMed]
[17] Tuñón-Suárez, M., Reyes-Ponce, A., Godoy-Órdenes, R., Quezada, N. and Flores-Opazo, M. (2021) Exercise Training to Decrease Ectopic Intermuscular Adipose Tissue in Individuals with Chronic Diseases: A Systematic Review and Meta-Analysis. Physical Therapy, 101, pzab162. [Google Scholar] [CrossRef] [PubMed]
[18] Wu, J. and Jacobson-Dickman, E. (2026) The Impact of Nutrition, Exercise, and Pharmacotherapy on Menstrual Health in Adolescents with Overweight and Obesity. Nutrition, 143, Article ID: 113021. [Google Scholar] [CrossRef
[19] Stefanaki, K., Karagiannakis, D.S., Peppa, M., Vryonidou, A., Kalantaridou, S., Goulis, D.G., et al. (2024) Food Cravings and Obesity in Women with Polycystic Ovary Syndrome: Pathophysiological and Therapeutic Considerations. Nutrients, 16, Article No. 1049. [Google Scholar] [CrossRef] [PubMed]
[20] Li, L., Kang, Z., Chen, P., Niu, B., Wang, Y. and Yang, L. (2024) Association between Mild Depressive States in Polycystic Ovary Syndrome and an Unhealthy Lifestyle. Frontiers in Public Health, 12, Article ID: 1361962. [Google Scholar] [CrossRef] [PubMed]
[21] Zeng, W., Luo, Y., Ou, J., Gan, D., Huang, M., Tomlinson, B., et al. (2025) Metformin in Polycystic Ovary Syndrome: Unraveling Multi-Stage Therapeutic Mechanisms from Puberty to Long-Term Health Outcomes. Frontiers in Pharmacology, 16, Article ID: 1654372. [Google Scholar] [CrossRef
[22] Ma, R., Ding, X., Wang, Y., Deng, Y. and Sun, A. (2021) The Therapeutic Effects of Glucagon-Like Peptide-1 Receptor Agonists and Metformin on Polycystic Ovary Syndrome: A Protocol for Systematic Review and Meta-Analysis. Medicine, 100, e26295. [Google Scholar] [CrossRef] [PubMed]
[23] Chen, H., Lei, X., Yang, Z., Xu, Y., Liu, D., Wang, C., et al. (2025) Effects of Combined Metformin and Semaglutide Therapy on Body Weight, Metabolic Parameters, and Reproductive Outcomes in Overweight/Obese Women with Polycystic Ovary Syndrome: A Prospective, Randomized, Controlled, Open-Label Clinical Trial. Reproductive Biology and Endocrinology, 23, Article No. 108. [Google Scholar] [CrossRef] [PubMed]
[24] Huang, R. and He, Y. (2025) The Safety and Efficacy of Liraglutide Combined with Metformin in Clinical Treatment of Polycystic Ovary Syndrome Patients: A Meta-Analysis. BMC Womens Health, 25, Article No. 282. [Google Scholar] [CrossRef] [PubMed]
[25] Shao, Y., Chen, Y., Zhu, M., Liu, Y., Fang, C., Wang, M., et al. (2024) DR10627, a Novel Dual Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity, 17, 1563-1573. [Google Scholar] [CrossRef] [PubMed]
[26] Jastreboff, A.M., Kaplan, L.M., Frías, J.P., Wu, Q., Du, Y., Gurbuz, S., et al. (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine, 389, 514-526. [Google Scholar] [CrossRef] [PubMed]
[27] Archana, P., Durai Ananda Kumar, T., Vijaya Ganesh, N., Mohammed, M., Pundalik Tavanoji, H., Deepikarani, R., et al. (2025) Decades Old Glitazones Still Find Niche in Drug Discoveries as PPAR-γ Agonists: Medicinal Chemistry Perspective, Structure-Activity Relationships and Therapeutic Implications. Bioorganic & Medicinal Chemistry, 131, Article ID: 118393. [Google Scholar] [CrossRef
[28] Sadeghi, H.M., Adeli, I., Calina, D., Docea, A.O., Mousavi, T., Daniali, M., et al. (2022) Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. International Journal of Molecular Sciences, 23, Article No. 583. [Google Scholar] [CrossRef] [PubMed]
[29] Williams, N.M., Randolph, M., Rajabi-Estarabadi, A., Keri, J. and Tosti, A. (2020) Hormonal Contraceptives and Dermatology. American Journal of Clinical Dermatology, 22, 69-80. [Google Scholar] [CrossRef] [PubMed]
[30] Chen, Z. and Cai, Z. (2022) Effects of Oral Contraceptives Plus Orlistat in Patients with Polycystic Ovary Syndrome and Overweight/Obesity: A Meta‐Analysis. Journal of Obstetrics and Gynaecology Research, 48, 1399-1408. [Google Scholar] [CrossRef] [PubMed]
[31] Sibal, R., Keogh, M., Latthe, P. and Idkowiak, J. (2026) Nonhormonal Pharmacological Interventions in Adolescent Polycystic Ovary Syndrome (PCOS): A Systematic Review. Journal of Pediatric and Adolescent Gynecology, 14. [Google Scholar] [CrossRef
[32] Kaplan, I., Bubley, G.J., Bhatt, R.S., Taplin, M., Dowling, S., Mahoney, K., et al. (2021) Enzalutamide with Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 110, 1416-1422. [Google Scholar] [CrossRef] [PubMed]
[33] Li, W., Zhang, X., Song, J., Yang, L., Wang, D., Yuan, G., et al. (2025) Mechanistic Insights into GLP-1 Receptor Agonist-Induced Weight Loss through Cerna Network Analysis. Genomics, 117, Article ID: 110988. [Google Scholar] [CrossRef] [PubMed]
[34] Nafie, M.S., Diab, M.K., Yassen, A.S.A., Elshamy, A.M., El Tohamy, M.R., Tawfik, H.O., et al. (2025) Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation. Drug Development Research, 86, e70192. [Google Scholar] [CrossRef
[35] Zeng, Y., Huang, Y., Liu, Y., Shen, X., Nie, Y., Wang, L., et al. (2025) Clomiphene Citrate Reduces Premature LH Surge in Obese Women during Controlled Ovarian Stimulation: A Retrospective Cohort Study. Frontiers in Endocrinology (Lausanne), 16, Article ID: 1512821. [Google Scholar] [CrossRef] [PubMed]
[36] Waanbah, B.D., Joseph, T., Rebekah, G., Kunjummen, A.T. and Kamath, M.S. (2021) Letrozole as First‐Line Drug for Ovulation Induction in Treatment‐naïve Infertile Polycystic Ovarian Syndrome Women. Journal of Obstetrics and Gynaecology Research, 47, 3583-3589. [Google Scholar] [CrossRef] [PubMed]
[37] Lentini, G., Querqui, A., Monti, N. and Bizzarri, M. (2025) PCOS and Inositols—Advances and Lessons We Are Learning. A Narrative Review. Drug Design, Development and Therapy, 19, 4183-4199. [Google Scholar] [CrossRef] [PubMed]
[38] Genazzani, A.D., Battipaglia, C., Foschi, M., Semprini, E., Aio, C., Spelta, E., et al. (2025) Improved Insulin Sensitivity and Reproductive Profile in Overweight/Obese PCOS Patients Undergoing Integrative Treatment with Carnitines, L-Arginine, L-Cysteine and Myo-Inositol. Gynecological Endocrinology, 41, Article ID: 2458710. [Google Scholar] [CrossRef] [PubMed]
[39] D’Anna, R., Corrado, F., Loddo, S., Gullo, G., Giunta, L. and Di Benedetto, A. (2021) Myoinositol Plus Α-Lactalbumin Supplementation, Insulin Resistance and Birth Outcomes in Women with Gestational Diabetes Mellitus: A Randomized, Controlled Study. Scientific Reports, 11, Article No. 8866. [Google Scholar] [CrossRef] [PubMed]
[40] Yazdanpanah, Z., Cheraghi, E., Nasrabadi, M.H. and Salehipour, M. (2024) Improvement in Biochemical Manifestations of the Serum and Follicular Fluid and ICSI Outcomes in PCOS Patients with Myo-Inositol Administration: Prospective Randomized Research. Naunyn-Schmiedebergs Archives of Pharmacology, 398, 7187-7198. [Google Scholar] [CrossRef] [PubMed]
[41] He, J., Deng, R., Wei, Y., Zhang, S., Su, M., Tang, M., et al. (2024) Efficacy of Antioxidant Supplementation in Improving Endocrine, Hormonal, Inflammatory, and Metabolic Statuses of PCOS: A Meta-Analysis and Systematic Review. Food & Function, 15, 1779-1802. [Google Scholar] [CrossRef] [PubMed]
[42] Fu, X., Cao, W., Ye, F., Bei, J., Du, Y. and Wang, L. (2024) Astaxanthin Compound Nutrient Improved Insulin Resistance, Hormone Levels, Embryo Quality and Pregnancy Outcomes in Polycystic Ovary Syndrome Patients Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection. Drug Discoveries & Therapeutics, 18, 296-302. [Google Scholar] [CrossRef] [PubMed]
[43] 姜欢, 姜玥, 张蛟. 白藜芦醇治疗多囊卵巢综合征机制研究进展[J]. 辽宁中医药大学学报, 2025, 27(6): 106-110.
[44] Zheng, N., Wang, C., Li, Y., Fu, H. and Hu, T. (2024) Myricetin Ameliorates Polycystic Ovary Syndrome in Mice by Brown Adipose Tissue Activation. Reproduction, 167, e240034. [Google Scholar] [CrossRef] [PubMed]
[45] Slouha, E., Segal, J., White, C., Pallotta, T., Ghosh, S., Clunes, L.A., et al. (2024) Ovarian Reserve and Hormone Alteration Following Laparoscopic Ovarian Drilling for Polycystic Ovarian Syndrome: A Systematic Review. Cureus, 16, e62092. [Google Scholar] [CrossRef] [PubMed]
[46] 胡三元, 刘少壮, 赵世刚. 减重代谢手术治疗肥胖症合并多囊卵巢综合征中国专家共识(2025年版) [J]. 中国普通外科杂志, 2025, 34(2): 183-189.
[47] 中华医学会外科学分会甲状腺及代谢外科学组, 中国医师协会外科医师分会肥胖和代谢病外科专家工作组. 中国肥胖及代谢疾病外科治疗指南(2024版) [J]. 中国实用外科杂志, 2024, 44(8): 841-849.
[48] Hu, L., Ma, L., Xia, X., Ying, T., Zhou, M., Zou, S., et al. (2022) Efficacy of Bariatric Surgery in the Treatment of Women with Obesity and Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 107, e3217-e3229. [Google Scholar] [CrossRef] [PubMed]
[49] 马雪琦, 王玲, 张春兰. 苍附导痰汤治疗多囊卵巢综合征的临床与机制研究进展[J]. 中国医药导报, 2025, 22(2): 81-84.
[50] 郭瑞. 苍附导痰汤加减治疗肥胖型多囊卵巢综合征临床研究[J]. 中国药业, 2017, 26(9): 70-72.
[51] 朱梓齐, 辛幸雨, 林寒梅. 苍附导痰汤加减联合二甲双胍治疗肥胖型多囊卵巢综合征疗效的Meta分析[J]. 中国民族民间医药, 2023, 32(23): 77-85.
[52] Hu, R., Geng, Y., Huang, Y., Liu, Z., Li, F., Song, K., et al. (2024) Jiawei Buzhong Yiqi Decoction Attenuates Polycystic Ovary Syndrome through Regulating Kisspeptin-GPR54-AKT-SHBG System. Phytomedicine, 133, Article ID: 155931. [Google Scholar] [CrossRef] [PubMed]
[53] 张红阳, 王晓姗, 王钦鹏. 启宫丸治疗痰湿证多囊卵巢综合征不孕疗效观察[J]. 现代中西医结合杂志, 2023, 32(23): 3268-3272.
[54] 姚雪, 杨春, 栗晓艳. 加味小陷胸汤辅治肥胖型多囊卵巢综合征临床观察[J]. 实用中医药杂志, 2024, 40(3): 453-455.
[55] 逯颖捷, 钱洁, 李彬. 基于数据挖掘探究针刺治疗多囊卵巢综合征选穴规律[J]. 中国中医药信息杂志, 2022, 29(11): 33-38.
[56] 沈凌宇, 梁翠梅, 杨文津. 通调带脉法针刺治疗腹部肥胖型多囊卵巢综合征的随机对照研究[J]. 针刺研究, 2018, 43(4): 255-259.
[57] 沈凌宇, 富小菲, 曾沁. 不同频率电针治疗腹部肥胖型多囊卵巢综合征的疗效比较[J]. 针刺研究, 2023, 48(12): 1266-1273.
[58] 马桂芝, 胡智海, 施茵. 穴位埋线联合二甲双胍对肥胖型多囊卵巢综合征患者糖脂代谢的影响[J]. 上海针灸杂志, 2020, 39(9): 1123-1127.
[59] 陈嘉欣, 王翰林, 谷彩山. 电针结合穴位埋线治疗肥胖型多囊卵巢综合征的临床研究[J]. 皮肤科学通报, 2019, 36(2): 245-249.
[60] 高远鹤, 李泊琳, 刘嘉玲. 耳穴法治疗多囊卵巢综合征的临床研究综述[J]. 临床医学进展, 2023, 13(8): 12732-12739.
[61] 柯维华, 王丽娟, 罗和平. 耳穴贴压治疗多囊卵巢综合征临床研究进展[J]. 亚太传统医药, 2024, 20(3): 238-242.
[62] 温静怡. 艾灸疗法对肥胖大鼠肠道菌群影响的研究[D]: [硕士学位论文]. 南宁: 广西中医药大学, 2019.